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ABSTRACT 
Protein-based drug carriers are an interesting alternative to traditional polymeric drug delivery 
systems due to their intrinsic biocompatibility and biodegradability. Electrospinning of neat 
proteins holds advantages over electrospinning of protein mixtures, e.g. whey isolates, such as 
better control of the physico-chemical and biological function of the resulting nanofiber-based 
system. In this study, we explore electrospinning of the isolated milk protein alpha-lactalbumin 
(ALA), which is a whey protein with important nutritional and pharmacological properties. Via 
waterborne electrospinning of ALA with a minimum amount of polyethylene oxide (PEO) as a co-
spininng polymer, nanofibers of high protein content were succesfully produced (up to 84% 
(w/w)). We demonstrate the ability to produce ALA-based nanofibers with a high degree of 
tunability in terms of size, stability in water and mechanical properties. The nanofibers displayed 
excellent biocompatibility in vitro as the viability of cultured TR146 human buccal epithelium and 
NIH 3T3 murine fibroblast cells was not influenced by exposure to ALA-based nanofibers. ALA-
based nanofibers were loaded with up to 6% (w/w) ampicilin and the nanofibers were capable of 
maintaining the activity of the antibiotic after electrospinning and cross-linking. Using such a 
property of the material, we demonstrate that ampicillin-loaded nanofibers succesfully inhibit the 
growth of Gram-negative bacteria in vitro. Importantly, after treatment with ampicillin-loaded 
nanofibers, no bacterial regrowth was observed, which indicates that this treatment may clear 
eventual persisters to ampicillin. Finally, the structual properties of the native functional protein 
were maintained after release of ALA from the nanofibers. This promotes our platform, not only 
as a sustainable protein-based drug delivery system, but also as an innovative solid form of ALA 
for food and pharmaceutical applications. 
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INTRODUCTION 
Drug delivery systems (DDSs) based solely on synthetic polymers often have lower 
biocompatibility compared to DDS composed of polymers of natural origin, which may limit their 
applicability.1 Protein- or peptide-based nanocarriers are an interesting alternative to other 
polymeric drug delivery systems due to their intrinsic biocompatibility and biodegradability.2 
Indeed, the large heterogeneity of proteins and peptides encoded in their primary amino acid 
sequence and the possibility of introducing chemical surface modifications hold great potential for 
a drug delivery platform with high tunability. Notwithstanding these extraordinary properties, 
high-performance protein-based DDSs are largely dependent on the morphology of the composite 
and, as a consequence, on a detailed control of the material development.  
Electrospinning of polymer or protein solutions is a versatile method to form elongated fiber 
structures. In healthcare, electrospun fibers have found specific applications as DDSs especially 
for topical administration, because of their high surface-to-volume ratio, porous structure, small 
size and ability to delivery drugs in a controlled manner.3 However, strong acids and/or toxic 
solvents are often employed to dissolve the polymers for electrospinning.4 This has recently 
induced an increasing demand of more sustainable approaches, namely waterborne 
electrospinning, i.e. electrospinning from aqueous phases to ease clinical translation. This, of 
course, poses some limitations on the range of molecules that can be electrospun.4 With this idea 
in mind, considerable efforts have recently been devoted to electrospin proteins with the possibility 
to use water and avoid harmful or toxic solvents for the electrospinning.2 A wide variety of proteins 
such as gelatin, collagen, elastin, and silk have successfully been electrospun into nanofibers.3,5 
The potential applications of protein-based nanofibers are diverse, and some have already been 
demonstrated e.g. insoluble bovine serum albumin (BSA)/PEO nanofibers as a two-dimensional 
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biosensor or as scaffolds for cell growth6, or BSA/polycaprolactone (PCL) nanofibers as a DDS 
for sustained release of nerve growth factor (NGF) over 28 days.7 Furthermore, successful attempts 
to electrospin whey protein isolates and other proteins such as beta-globulin were reported.8–10 
However, electrospinning of whole protein mixtures may limit the bioactivity of a specific protein 
component of interest in the mixture, as well as posing some constraints in the range of tunability 
of the final material.  
Milk proteins represent ideal vectors for drug delivery due to their inherent role as vehicles that 
deliver small molecules in vivo.11 Moreover, they are cheap and readily available, which make 
them attractive for commercial use.11,12 Alpha-lactalbumin (ALA) is a 14.2 kDa protein, a 
significant component of whey, which has several favorable properties, not only related to its 
nutritional function. Clinical studies showed that an ALA-enriched diet was beneficial to patients 
vulnerable to stress by reducing cortisol levels and increasing cognitive and motor 
performances.13–15 In healthy subjects, administration of ALA increased sustained alertness and 
reduced sleepiness.16 ALA has been added to infant formula due to its intrinsic safety and for its 
ability to induce weight gain and prevent atopic dermatitis.17–19 In its original, methylated or 
chemically modified form, ALA showed inhibiting activity towards human immunodeficiency 
virus 1 (HIV-1), herpes simplex virus (HSV), and human cytomegalovirus.20 Furthermore, a 
partially unfolded form of ALA in combination with oleic acid, called HAMLET (human alpha-
lactalbumin made lethal to tumor cells), exerts in vitro a robust anticancer activity against a variety 
of tumor cell types.21,22 In vivo, HAMLET has been reported to show efficacy against papilloma, 
bladder cancer, glioblastoma, and colon cancer.23–26 In addition, the complex formed by bovine 
ALA and oleic acid, called BAMLET, has shown similar antitumor properties.27 For all the above 
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cases, designing efficient formulations of ALA-based complexes both in terms of stability and 
capability of interacting with biological interfaces/barriers is fundamental.  
Here, we successfully present a waterborne electrospinning protocol for the production of 
biocompatible electrospun ALA/PEO nanofibers. Besides the possibility to electrospin ALA 
without the use of any organic or toxic agents and with a minimum amount of co-polymer, we also 
report a unique, easily scalable, tunability of our system. Size, mechanical properties and 
wettability of the produced ALA nanofibers can indeed be rationally tuned by controlling the 
protein concentration and/or via a non-destructive, simple and sustainable post-production 
treatment, which is a true novelty for materials composed by almost-net protein content. Most 
importantly, besides the above mentioned versatility, ALA nanofibers are capable of encapsulating 
the antibiotic ampicillin, preserving the functionality of the antibiotic and facilitating its delivery. 
We demonstrate this via monitoring the efficacy of ampicillin-loaded nanofibers to inhibit the 
growth of relevant Gram-negative bacteria and eventually also clearing persisters bacteria to 
ampicillin. Last but not least, ALA in the form of nanofibers maintains its structural native features, 
which paves the way for conceptually novel solid formulations of biologics with enhanced stability 
and interesting interaction with biological interfaces.  
MATERIALS AND METHODS 
Materials 
Alpha-lactalbumin powder was kindly provided by Davisco Food International/Agropur 
Ingredients, Eden Prairie, MN, USA (batch number: JE 010-5-410, 92.5% purity). Polyethylene 
oxide (PEO, Mw 300 kDa), 25% (w/w) glutaraldehyde, Dulbecco’s Modified Eagle’s Medium - 
high glucose, L-glutamine, penicillin, streptomycin, Hank’s Balanced Salt Solution (HBSS) and 
phenazine methosulfate (PMS) were purchased from Sigma-Aldrich (St. Louis, MO, USA). NIH 
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3T3 cell line was from American Type Culture Collection (ATCC, Manassas, VA, USA). TR146 
cell line was kindly provided by the Imperial Cancer Research Technology (London, UK) with 
generous help from Prof. E.B. Lane (The University of Dundee, UK). Fetal bovine serum (FBS) 
was purchased from PAA laboratories (Brøndby, Denmark). Newborn Calf Serum (NCS) was 
obtained from Life Technologies (Carlsbad, CA, USA). N-2-hydroxyethylpiperazine-N’-2-
ethanesulfonic acid (HEPES) was from PanReac AppliChem (Damstadt, Germany). 3-(4,5-
dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) (MTS) 
was obtained from Promega (Madison, WI, USA). Lysogeny broth (LB) medium (10 g/L tryptone, 
5 g/L yeast extract, and 0.5 g/L NaCl) and LB agar plates (LB with 15 g/L agar) were used for 
planktonic growth and the growth inhibition study, respectively. Escherichia coli BW25113 were 
purchased from Dharmacon (GE Healthcare, Chicago, Illinois). Pseudomonas aeruginosa PA14, 
Burkholderia thailandensis E264, E. coli ATCC11303, and E. coli BW25113 carrying an 
ampicillin resistance cassette were kindly provided by Dr. E. Westra, Prof. R. Titball, and Dr. B. 
Temperton at University of Exeter, and Dr. D. Summers at the University of Cambridge, 
respectively. Ultrapure water was obtained by purification on a PURELAB flex system (ELGA 
LabWater, High Wycombe, UK).  
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Preparation of samples for electrospinning 
A list of samples is provided in Table 1. A 7.4% (w/w) dispersion of PEO in ultrapure water was 
mixed in the ratio 1:1 (w/w) with ALA solutions prepared in ultrapure water with ALA 
concentrations of 4.8, 9.1, 16.7, 23.1, 28.6 and 37.5% (w/w) to obtain a final ALA content in the 
electrospun fibers of 39, 55, 69, 76, 79, 84% (w/w), respectively (Table 1).  
For the production of ampicillin loaded fibers, ampicillin was dissolved in the ALA solution, 
which was mixed 1:1 (w/w) with a 7.4% (w/w) PEO dispersion and electrospun according to the 
method described above. A 37.5% (w/w) solution of ALA was prepared in ultrapure water. 76.8, 
37.2 or 12.2 mg ampicillin per g of ALA was added to the protein solution to achieve the final 
ampicillin content in the dry nanofibers of 6%, 3% or 1% (w/w), respectively.  
Table 1. PEO and ALA stock solutions of the listed concentration were mixed in the ratio 1:1 
(w/w) and electrospun. The final PEO and ALA contents in the dry nanofibers are specified. 
Sample names are provided and will be used in the main text. 
Sample name Concentration (solution),  
% (w/w) 
Content (nanofibers),  
% (w/w) 
 PEO ALA PEO ALA 
ALA/PEO-0 7.4 - 100 - 
ALA/PEO-39 7.4 4.8 61 39 
ALA/PEO-55 7.4 9.1 45 55 
ALA/PEO-69 7.4 16.7 31 69 
ALA/PEO-76 7.4 23.1 24 76 
ALA/PEO-79 7.4 28.6 21 79 
ALA/PEO-84 7.4 37.5 16 84 
ALA/PEO-100 - 37.5 - 100 
 
Characterization of protein/polymer entanglement by rheology 
A steady state flow test was conducted using an AR-G2 rheometer (TA Instruments, Waters 
Corporation, Raleigh, NC, USA) equipped with a cone of an angle of 1o and a diameter of 60 mm. 
The viscosity was determined at shear rates from 10–1000 s-1 at 25oC with a 5 minutes equilibration 
period prior to each measurement. The tolerance was set to 5% with a maximum measuring time 
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of 1 min for each shear rate. Measurements which did not reach equilibrium (5% deviation) within 
1 min were excluded.  
Electrospinning of ALA-based nanofibers and crosslinking 
ALA/PEO dispersions were stirred for at least 30 min prior to electrospinning. The electrospinning 
was conducted on a horizontal electrospinning setup including a high voltage generator (ES50P-
10W, Gamma High Voltage Research, Ormond Beach, FL, USA), and a collector plate covered 
with aluminum foil. The flow of the dispersion for electrospinning (1 mL/hours, 20G needle) was 
controlled by a syringe pump (New Era Pump Systems, Farmingdale, NY, USA). The 
electrospinning was carried out at 15-16 kV at room temperature (20±2oC) with a relative 
humidity of less than 30% with a distance of 15 cm to the collector plate. 
To improve the stability of the nanofibers in aqueous medium, glutaraldehyde (GTA) vapor was 
used for cross-linking. Nanofibers were placed on a support located above a petri dish containing 
20 mL of 25% (w/w) GTA solution in a closed container. An illustration of the setup can be found 
in Supporting Information Figure S1. The nanofibers were air-dried for 24 hours under the fume 
hood to evaporate excess GTA after the cross-linking treatment.  
Assessment of nanofiber morphology by scanning electron microscopy (SEM) 
The fibers were visualized by scanning electron microscopy (SEM, Phenome Pro X, Phenom-
World, Eindhoven, The Netherlands). The diameter of the fibers was evaluated from at least 15 
SEM images taken of each samples using ImageJ software (National Institute of Health, 
Bethesda, MD, USA) with at least 300 size measurements per sample. 
Composition analysis by Fourier Transform Infrared Analysis (FTIR) 
FTIR analysis was conducted on solid dry samples on a Bomem MB-Series spectrophotometer 
(Bomem, Quebec, QC, Canada) with an Arid-Zone™ light source spectrometer based on a 
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universal attenuated total reflectance FTIR sensor equipped with DuraScope diamond ATR 
(SensIR Technologies, Danbury, CT, USA). Absorbance spectra (an average of 16 scans) were 
recorded in the range of 4000-600 cm-1 with a spectral resolution of 2 cm-1. 
Disintegration test of ALA-based nanofibers 
The nanofibers were punched into disks of 10 mm in diameter and immersed in 2 mL ultrapure 
water for 24 hours at room temperature. Hereafter, the disks were dried under air flow for a 
minimum of 24 hours and the weight loss determined according to the following equation (Eq. 1):  
Weight loss (%) =
Wi − Wf
Wi
∙ 100%          (Eq. 1) 
Where Wi is the initial weight of the 10 mm fiber discs and Wf is the final weight of the fiber disks 
after being immersed in water for 24 hours and dried for a minimum of 24 hours.  
Protein structure determination by circular dichroism (CD) 
ALA/PEO-84 nanofibers were disintegrated in ultrapure water to a final concentration 0.12 mg 
nanofibers per mL, which was equivalent to 0.10 mg/mL ALA and 0.02 mg/mL PEO. As controls, 
0.1 mg/mL neat ALA and 0.02 mg/mL PEO dissolved in ultrapure water were used. Far-UV 
measurements (190–250 nm) were performed on a Chirascan Applied Photophysics CD 
spectrometer (Applied Photophysics, Leatherhed, UK) equipped with a water bath temperature 
control system set at 25oC. A rectangular 10 mm path length quartz cuvette (Hellma Analytics, 
Müllheim, Germany) was used. Spectra were collected with a 0.5 nm data interval, a 1 s measuring 
time per point and a spectral band width of 1.0 nm. Three scans were recorded and averaged for 
each sample, which was analyzed in duplicates. The CD data was smoothed by a 4-point Savitzky-
Golay algorithm.  
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Characterization of mechanical properties of electrospun ALA-based nanofibers  
The mechanical properties of untreated and GTA cross-linked electrospun ALA-based nanofiber 
were characterized at room temperature in a TA.XT plus texture analyzer (Stable Micro Systems, 
Godalming, UK), with a maximum load of 50 N in the loading cell, a resolution of 1 N, a test 
speed of 2 mm/s and a gripping distance of 20 mm. Rectangular-shaped samples of approximately 
35×20 mm were cut from the original nanofiber mats and adjusted into the metal grips of the 
texture analyzer. Stress versus strain curves were obtained, and the slope of the linear part of the 
curve, corresponding to the elastic behavior, was calculated as the Young's modulus.28 
Biocompatibility of ALA-based nanofibers assessed in vitro 
TR146 (human squamous cell carcinoma, buccal) and NIH 3T3 (murine embryonic fibroblast) 
cells were cultured in Corning Costar polystyrene culture flasks (175 cm2, Sigma Aldrich) in 
DMEM supplemented with L-glutamine (2 mM), penicillin (100 U/mL), streptomycin (100 
µg/mL) and FBS (10% (v/v)) for TR146 cells and NCS (10% (v/v)) for NIH 3T3 cells, in a 
humidified incubator at 37oC with 5% CO2. 100.000 TR146 cells/well or 50.000 NIH 3T3 
cells/well were seeded in flat-bottom, transparent 12-well plates (Thermo ScientificTM NuncTM 
NunclonTM Delta Surface) and cultured for 48 hours under the aforementioned conditions. The 
cells were washed twice in 2 mL warm 10 mM HEPES in HBSS pH 7.4 (hHBSS) prior to exposure 
to the fibers. Small nanofibers mats of 10 mm in diameter were placed in 2.5 mL hHBSS on top 
of the cell layer or placed in stainless steel baskets mounted above the cell layer, and the cells were 
incubated for 4 hours at 37oC. Short term exposure was used to avoid cell proliferation and 
differentiation to influence the results. After treatment, the nanofibers were removed (to the extent 
possible) and the cells were washed twice in hHBSS pH 7.4 and the cell morphology was 
visualized under an Eclipse Ti-S microscope (Nikon, Tokyo, Japan). The viability of the cells after 
exposure was evaluated by the MTS/PMS colorimetric assay. The cells were incubated at 37oC for 
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45-120 min with 1 mL reagent solution containing 240 µg/mL MTS and 2.4 mg/mL PMS in 
hHBSS buffer with mild shaking (50 rpm). Hereafter, 100 µL in quintuplicate of the metabolized 
MTS/PMS solution from each well was transferred to a transparent 96-well plate and the 
absorbance was measured at λ=492 nm in a plate reader (POLARstar OPTIMA, BMG LABTECH, 
Ortenberg, Germany).  
Study of bacteria growth inhibition by ALA-based nanofibers 
Overnight cultures were prepared by picking a single colony of Escherichia 
coli BW25113, Pseudomonas aeruginosa PA14, Burkholderia thailandensis E264, Escherichia 
coli ATCC11303, or Escherichia coli BW25113 carrying an ampicillin resistance cassette from a 
streak plate, followed by growth of the bacteria in 200 mL fresh LB broth in a shaking incubator 
at 200 rpm and 37 °C for 17 hours. 200 µL of an overnight culture was pipetted onto LB agar plates 
and spread evenly with an L-spreader before being left to dry at room temperature in a flow hood. 
Each agar plate was divided into four areas. Since we aimed at developing an approach for 
eradicating microbes growing on surfaces i.e. for topical delivery and acting in the immediate 
proximity of the bacteria, 10 mm diameter fiber mats containing 0, 1, 3, or 6% (w/w) ampicillin 
were deposited in the center of each area either immediately after inoculating bacteria on agar (lag 
phase inhibition), or 2.5 hours after inoculation (exponential phase inhibition), or 17 hours 
after inoculation (stationary phase inhibition). Plates were incubated at 37 °C for 24 hours and 
imaged with a camera every hour for the first 6 hours in order to follow the formation of the 
inhibition area. In order to compare inhibition against different Gram-negative species and for 
different phases of growth, the inhibition area was calculated relative to the fiber mat area. Each 
measurement was performed at least in triplicate, graphs reporting their mean and standard error 
of the mean. 
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RESULTS AND DISCUSSION 
The degree of entanglement of ALA with PEO depends on ALA concentration 
 
Several parameters influence the electrospinning process and specifically the morphology of the 
resulting nanofibers.1 The physico-chemical properties of the solution to be electrospun can be 
adjusted to tune the production of fibers with specific features. In this regard, the rheological 
behavior of the solution is crucial for electrospinning and directly related to the intermolecular 
entanglement between the macromolecules in bulk.29 Sufficient entanglement is indeed required 
to facilitate fiber formation during electrospinning. 
To investigate the effect of PEO on the ALA solutions and monitor the molecular interaction 
between ALA and PEO, a rheological characterization of ALA/PEO mixtures was performed. 
Names corresponding to the content of ALA in the samples tested are provided in Table 1. The 
viscosities of the neat ALA solutions were low even at high protein concentrations (up to 18.75% 
(w/w), ALA-84) and overall showed Newtonian behavior (i.e. the viscosity is independent of shear 
rate); two properties indicative of limited intermolecular entanglement (Figure 1A, circles). As 
expected, the neat PEO dispersion was viscous, showed non-Newtonian behavior and displayed 
shear thinning properties (Figure 1A, green triangles). Importantly, these properties were 
maintained in the ALA/PEO blend dispersions, which all showed clear shear-thinning behavior 
(Figure 1A, diamonds). It is noticeable that the protein-polymer blend had a significantly higher 
viscosity than the neat PEO dispersion. Mixing ALA with PEO promoted an expected change in 
the arrangement of the macromolecules in the bulk through interactions between the polymer and 
the proteins, which leads to a restriction in the fluid flow and thus an increase in viscosity. 
According to Hassen et al.29, the strength of binding between the protein and the polymer of 
interest (hereafter named the ‘component of entanglement’) can be assessed by subtracting the 
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viscosity coefficient for the individual components in the dispersion, i.e. ALA and PEO, from the 
total viscosity coefficient of the blend measured at the same conditions (namely concentration, 
temperature and shear rate). The component of entanglement increased with increasing 
concentrations of ALA, and decreased slightly with increasing shear rates, as some of the protein-
polymer entanglement may be broken under shear (Figure 1B). The results clearly indicate that 
ALA and PEO strongly entangle, which is essential for successful electrospinning of the 
ALA/PEO blend dispersions. 
Native proteins often have limited intermolecular entanglement, and unfolding of the proteins are 
often necessary to facilitate their electrospinning.30 However, the protein bioactivity, which is 
related to their three-dimensional folding, may significantly be reduced if denaturation occurs. 
Therefore, it is ideal to maintain the intact native structure of the protein, while increasing the 
overall viscosity of the solution by other means. An alternative strategy to effectively electrospin 
proteins in their native form is to blend in a high molecular weight ‘carrier’ polymer to increase 
the viscosity of the protein solution, and hereby facilitate the electrospinning of the protein.31 PEO 
is a water-soluble and biocompatible synthetic polymer with excellent ability to be electrospun6 
and furthermore favorably interact with ALA (Figure 1B). For these reasons, PEO was chosen as 





Figure 1. A) Rheological characterization of neat ALA solution, neat PEO and ALA/PEO blend 
dispersions. B) Component of entanglement for ALA/PEO blend dispersions determined 
according to Hassen et al.29. Curves represent the average viscosity at the given shear rate. N=2, 
n=2-3. N represents the number of samples, and n represents the number of measurements per 
sample. Data is represented as mean. Standard deviation were below 5.6x10-4 Pa s and 3.8 x10-2 
Pa s for neat ALA samples and samples containing PEO, respectively. 
 
ALA content determines nanofiber morphology and size 
The morphology and diameter of electrospun nanofibers are very important for their functionality 
and biological performance.32,33 It was not possible to produce fibers without PEO due to a low 
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degree of intermolecular entanglement and hence low viscosity of the neat ALA solutions. The 
degree of entanglement is a critical parameter for the formation of nanofibers without artifacts (e.g. 
beading), and the viscosity and degree of entanglement with PEO were highly dependent on the 
ALA concentration (Figure 1). Accordingly, the formation of the protein-based nanofibers was 
expected to be highly dependent on the ALA to PEO w/w ratio. Nanofibers of neat PEO 
electrospun from 3.7 % (w/w) PEO in water were extensively beaded (Figure 2). The presence of 
beads is often considered as a sign a poor quality of the nanofibers, leading to a high heterogeneity 
of the material. Fibers with a significant presence of beads at a low ALA concentration were also 
observed (Figure 2A, top). By increasing the concentration of ALA, the bead formation 
diminished, and at an ALA content of 76% (w/w) (ALA/PEO-76) thin uniform fibers were 
produced (Figure 2A, bottom). The entanglement of polymer with protein is a central driving force 
for high quality fiber production. ALA/PEO-39 and ALA/PEO-55, which form beaded fibers, have 
a similar component of entanglement, which is ~10 times lower than the component of 
entanglement for ALA/PEO-76, which forms beadless fibers (Figure 1B). Thus, a good correlation 
between the degree of entanglement and the quality of the electrospun fibers was observed, and it 
shows that the formation of beadless fibers can be predicted by the absolute increase in viscosity 
due to interactions between ALA and PEO.  
The average diameter of the electrospun nanofibers increased with increasing ALA concentration 
as can be qualitatively seen from the SEM images (Figure 2A, bottom) and from the diameter 
analysis (Figure 2B). Even small changes in the concentration of ALA induced significant 
differences in the diameter of the nanofibers. Indeed, changing the protein content in the nanofibers 
from 76% (w/w) (ALA/PEO-76) to 84% (w/w) (ALA/PEO-84) resulted in an increase in the 
average fiber diameter from 390±61 nm to 600±111 nm, demonstrating the excellent size tunability 
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of the ALA-based fibers with high protein content. In this size range, nanofibers systems present 
a quite high efficiency as delivery system as shown, e.g. by the fast release of the anticancer drug 
paclitaxel from poly(lactic-co-glycolic acid)(PLGA) nanofibers (770±13 nm) when compared to 
micrometer sized (2.5±0.32 µm) PLGA fibers.32 Similarly, Chen et al., also showed that the 
release of 5-fluorouracil from poly(lactic acid) fibers was higher for fibers with a smaller diameter 
(0.35±0.11 µm) compared to larger diameter (1.02±0.37 µm).39 In the context of tissue 
engineering, the size of the nanofibers also affects their interaction with cells.34 For example, fibers 
with larger diameters (600±110 nm) allowed deeper migration into the scaffold of osteoblastic 
cells after longer cultivation.34 In contrast, thinner nanofibers (110±40 nm) showed improved cell 
differentiation.34 As a consequence, the possibility of modulating the fiber diameter is crucial for 
tailoring the nanofiber-based platform to the desired biological response.  
Globular proteins such as ALA fold into three-dimensional structures, carry multiple charges on 
their surfaces and may expose hydrophobic pockets. This also makes such globular proteins 
especially versatile for encapsulation of hydrophobic, polar, and ionic drugs. Specifically, ALA 
has been shown to interact with ions, other proteins and lipid membranes.35,36 We speculate 
whether ALA could potentially be used as a tunable platform to carry other bioactive 
macromolecules such as polymeric carbohydrates, lipids, natural oils or other proteins, and hereby 
produce natural biocompatible nanofibers with specific functional or biological properties. For 
example, electrospun nanofibers of high ALA-content in complex with oleic acid could be an 
improved formulation of HAMLET/BAMLET in the form of biocompatible and bioactive 
nanofibers for the treatment of cancers.  
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Figure 2. A) Scanning electron micrographs of nanofibers produced by electrospinning of ALA 
and PEO. Red arrows indicate beading. 10,000x magnification. B) Size distributions of electrospun 
ALA/PEO nanofibers without beading (i.e. ALA/PEO-76, -79, -84) and of increasing ALA 
content. The average fiber diameter is provided with standard deviations. N=3, n>300. N is the 
number of samples and n is the number of fibers measured.  
 
ALA-based nanofibers with excellent water stability were produced by crosslinking 
with GTA 
 
Both fast-dissolving and dosage forms with higher integrity in water have applications in drug 
delivery. As expected, the hydrophilicity of both ALA and PEO leads to ALA/PEO electrospun 
fibers that instantly disintegrated when exposed to an aqueous medium. This property is 
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advantageous for some applications but may represent a limiting step for the effective use of the 
material in other cases. GTA has been used as an affordable and effective protein crosslinking 
agent for several protein-based nanofibers consisting of e.g. collagen and gelatin.37,38 To increase 
the stability of the ALA/PEO fibers, a crosslinking treatment with GTA vapor was performed. An 
illustration of the setup is found in Figure S1. GTA vapor was used to limit the amount of adsorbed 
GTA in the nanofibers that may result in a reduced biocompatibility of the fibers.38 After treatment 
of the fibers with GTA vapor, a colour shift from white to yellow was observed. This is indicative 
of the formation of aldimine bonds (CH=N) between the free amino groups of ALA and aldehyde 
groups of GTA, as previously observed.37,38 Nanofibers conserved their nanofibrous morphology, 
but seemed more intertwined and bended following cross-linking (Figure 3A).  
This re-arrangement of the fibers within the mat significantly changes their stability in water. The 
nanofibers were immerged in water for 24 hours and the weight loss determined. Already after 
eight hours of exposure to GTA vapor and in sharp contrast to the fast-dissolving non-cross-linked 
ALA/PEO nanofibers, the ALA/PEO fibers did not macroscopically disintegrate, proving a 
significantly increased stability of the fibers in aqueous solution. Exposure to GTA for more than 
8 hours did not provide a significant increase in nanofibers stability with a weight loss in the range 
of 10-12% (Figure 3B). Moreover, immersion of ALA/PEO fibers in water did not change the 
morphology of the individual fibers, but the fibrous network appeared even more intertwined 
(Figure 3A). This could be related to partial dissolution after immersion in water due to the 
presence of non-cross-linked PEO as reported by others.10 Cross-linking the ALA-based 
nanofibers by heat was also explored by incubating the ALA-based nanofibers at 90oC for 8-24 
hours (Supporting Information, Figure S2). This treatment increased the stability of the ALA-
based nanofibers to the same extent as the treatment of the nanofibers with GTA vapor. However, 
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subsequent visualization of the fibers revealed significant loss of their fibrous structure 
(Supporting Information, Figure S2). Cross-linking of neat PEO nanofibers by heat at 80oC was 
reported to form a coherent PEO film with no fiber structure.10 Melting of PEO in the ALA-based 
nanofibers most likely explains the loss of structure. The fibrous structure is of great importance 
for the biological performance of the nanofibers. The use of heat for cross-linking the ALA-based 
nanofibers was not explored further due to the superior ability of GTA vapor to both cross-link, 
but also retain the structure of the nanofibers after cross-linking.  
Figure 3 shows that both highly soluble and also “water stable” nanofibers can be produced from 
the same ALA-based platform. This significantly broadens the number of potential medical 
applications for which the use of ALA/PEO nanofibers could be explored further. Highly water-
soluble electrospun nanofibers could be an alternative dosage form to the fast-dissolving films and 
tablets for a fast onset of action, which can increase the drug bioavailability by fast and local drug 
release.39 These can be administrated with little or no water, which is beneficial for patients with 
swallowing difficulties.39 For example, fast dissolving tables with paracetamol (amoung others 
Pinex Smelt®) or Olazapine (tradename Zyprexa®) have been marketed by Teva and Eli Lilly as 
analgesics and antipsycotic agents, respectively. Oral ultrafast-dissolving drug delivery systems 
have been also developed using electrospun ultrafine polyvinyl alcohol (PVA) nanofibers; caffeine 
with high water solubility and riboflavin with poor solubility were assessed as model drugs.40 In 
contrast, for sustained drug release increased stability of the nanofibers in aqueous solution is 
required. For example, multilayered gelatin nanofibers partially cross-linked with GTA was shown 
to exhibit sustained zero-order drug release with almost complete elimination of the initial burst 
release.41 In tissue engineering, cross-linking of protein nanofibers to retain the fibrous structure 
is often nessesary for the fibers to act as a scaffold to facilitate cell migration and differentiation.34 
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Figure 3. A) Scanning electron micrographs of non-treated (ALA/PEO-84), cross-linked (GTA 
vapor, 24 hours) and cross-linked (GTA vapor, 24 hours) ALA/PEO-84 nanofibers after exposure 
to water for 24 hours, 10,000x magnification. B) Weight loss of ALA/PEO-84 nanofibers after 
exposure to water for 24 hours. N=2, n=3, where N is the number of samples and n is the number 
of measurements per sample. Error bars represent standard deviations. 
 
ALA content and crosslinking affect the mechanical properties of ALA-based 
nanofibers 
 
To verify the composition of the produced nanofibers, FTIR spectroscopy analysis was conducted 
(Figure 4A). Distinct regions in the FTIR spectra could be identified. ALA in powder form showed 
peaks at approximately 3280 cm-1 and 1643 cm-1 representing the vibrational stretching of N–H  
and C=O, respectively. PEO is characterized by C–H2 stretching around 2900 cm
-1 and C–O–H 
stretching at 1100/958 cm-1. The FTIR absorbance spectrum of the fibers confirms the 
simultaneous presence of these peaks, which indicate that ALA and PEO co-exist in the fiber 
structure. Furthermore, no significant differences in the FTIR absorbance spectrum were observed 
after cross-linking with GTA and the GTA-treated ALA/PEO nanofibers did not show evident 
structural differences even after incubation in water for 24 hours. This indicates that both ALA 
and PEO are cross-linked into the nanofiber matrix, which demonstrate once more the efficacy of 
the GTA cross-linking process.  
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The CD spectrum of native ALA (Figure 4B) shows characteristic minima at 208 nm and 212-225 
nm indicative of an α-helical structure of the protein in water. The presence of PEO did not affect 
the secondary structure of ALA (Figure 4B). Importantly, ALA retained its native structure after 
electrospinning and subsequent release after dissolution of ALA/PEO-84 nanofibers in water 
(Figure 4B). The importance of ALA as a nutrient should not be underestimated.13-19 As ALA 
retains its native structure after electrospinning, nanofibers of ALA could be an alternative solid 
form of the milk protein with beneficial nutritional value. For example, protein nanofibers have 
been proposed as carriers of flavors or nutraceuticals.10 Electrospun nanofibers have also been 
suggested as potential texture modifiers in food,10 and having intact ALA in the form of tunable 
nanofibers would clearly offer a broader range of potential applications. Biologics e.g. proteins are 
the fastest growing class of pharmaceutics due to their high specificity and potency but often have 
low physico-chemical stability, which poses a great challenge in their formulation and storage.42 
Electrospinning may be an alternative to the conventional techniques such as freeze drying and 
spray drying to produce a new solid form, which can retain the native structure and the bioactivity 
of the protein.42 
The mechanical properties of the nanofibers are also important parameters that can have a 
significant effect on their biological performance. The results presented in Figure 4C show that 
the mechanical properties of ALA/PEO can be modulated. The Young’s modulus of the nanofibers 
significantly depended on ALA content with the stiffness of the fiber material decreasing with 
increasing ALA content (Figure 4C). This could indicate that a higher PEO to ALA ratio in the 
fibers improves their mechanical properties, which make them more resistant to mechanical stress.  
Improving the mechanical performance of nanofibers after GTA-crosslinking has been widely 
reported in literature.43–45 Specifically, the modulus of starch or gelatin fibers increased nine-fold 
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and almost ten-fold, respectively. The stiffness of the ALA-based nanofibers increased after cross-
linking by exposure to a GTA vapor for 24 hours (Figure 4C). This is not surprising as enhanced 
bonding and intersection points are induced by the GTA treatment, which create a more robust 
inter-fiber web (Figure 3A).43 Furthermore, this tensile strength study was consistent with visual 
and tactile examination of the fibers: decreased ALA content fibers resulted in less flexible and 
easily breakable fibers, while GTA-crosslinking enhanced the stiffness of the fiber material. 
Altogether, these data shows that the mechanical properties of the ALA/PEO nanofibers can be 
finely modulated both by changing the parameters of the electrospun solution and via post-
production treatment by GTA. Wingate et al. have demonstrated that differentiation of 
mesenchymal stem cells can be modulated by differences in the elasticity of the nanofiber-based 
scaffold.46 This was proposed as a new tool for tuning vascular tissue regeneration.46 Nanofibers 
are especially suitable for topical administration for e.g. wound healing or transdermal drug 
delivery.3 In general, a reduction in stiffness and thus an increased flexibility can make the material 
more easily adaptable to curved surfaces of the human body, e.g. in the oral cavity or certain areas 
where the skin stretches and contracts such as in joints. Thus, the mechanical properties of the 
ALA-based nanofiber could potentially be adapted to the biological purpose by small changes in 




Figure 4. A) Representative FTIR absorbance spectra of neat PEO, neat ALA, non-treated fibers 
and ALA-based fibers cross-linked with GTA vapor (24 hours). The ATR crystal absorbs around 
2000 cm-1 and these data points are excluded. N=3. B) Representative CD spectra of neat ALA, 
neat PEO, ALA and PEO mixture, and ALA and PEO released from electrospun ALA/PEO-84 
nanofibers. N=2, n=2. C) Young's modulus of electrospun ALA/PEO-76, -79- and 84 nanofibers 
as well as cross-linked ALA/PEO-84 nanofibers. N=2, n=3; N represent the number of samples 




ALA-based nanofibers display good biocompatibility in vitro 
 
ALA, as a whey protein, is biocompatible and biodegradable11, which makes it an appropriate 
macromolecule to consider for biomedical purposes. PEO is classified as an ‘Inactive Ingredient’ 
by the FDA (FDA UNII 16P9295IIL). To evaluate the biocompatibility of the electrospun ALA-
based nanofibers, cultured cell monolayers from the TR146 (human buccal epithelium) and NIH 
3T3 (murine fibroblast) cell lines were exposed to non-treated and cross-liked ALA-based 
nanofibers for 4 hours (Figure 5). A few areas of cells were affected by the free-floating cross-
linked ALA-based nanofibers and showed changes in cell morphology e.g. cell rounding. This 
happened only if the fibers were in contact with the cells, and it did not affect the overall viability 
of the cells. To exclude contact-dependent changes due to the physical contact of fibers with the 
cell monolayer as reported by others47, the cross-linked nanofibers were placed in baskets above 
the cell monolayer (i.e. exposure of the cell to the fibers, but not in direct contact, see Materials 
and Methods section). As the non-cross-linked fibers dissolved instantly when exposed to an 
aqueous medium, placing these fiber disks in baskets was not necessary. Exposure of TR146 and 
NIH 3T3 cell monolayers to the ALA-based nanofibers did not induce changes in the cell 
morphology nor in the cellular viability compared to the control (Figure 5A). GTA is widely used 
in the medical field as a disinfectant for surgical instruments and has been formulated as a 
treatment for warts (Brand name Glutarol®, 10% GTA (w/v)). Upon exposure, GTA can cause 
irritation of the eyes, skin and respiratory tract and in higher doses induce acute toxicity. The 
nanofiber were only exposed to minute amounts of GTA by cross-linking the nanofiber in GTA 
vapor and not by submerging the fibers in GTA solution. The fibers were not washed prior to 
exposure to the cells in the biocompatibility assay. Accordingly, data in Figure 5B shows that the 
treatment (GTA vapor) used to improve the aqueous stability of the fiber material did not affect 
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its compatibility towards the cell models tested. Due to the good biocompatibility of both ALA 
and PEO, it was not surprising that the ALA-based nanofibers displayed no toxicity. In the context 
of clean and environment-friendly production of biomaterials4, it should be noted that the ALA-
based nanofibers were electrospun in water as a solvent, which makes the setup simple and 
circumvents the need for organic toxic solvents, which are often used to aid the electrospinning 
process.1 This fully water-borne fabrication method represents a great advantage compared to 
traditional electrospinning of polymers in strong acids and/or toxic solvent systems.4 It makes our 
materials appealing as a safe and biocompatible platform with potential application in medical 
fields such as tissue engineering and drug delivery.     
    
Figure 5. A) Bright-field microscopy images of TR146 and NIH 3T3 cell monolayers exposed for 
4 hours to ALA/PEO-84 nanofibers non-treated and cross-linked by GTA vapor (24 hours). Cross-
linked ALA/PEO-84 nanofibers were placed in baskets above the cells. All images were acquired 
at 40x magnification. Scale bar 100 µm. B) Relative cell viability of TR146 and NIH 3T3 cell 
monolayers exposed for 4 hours to non-treated and cross-linked ALA/PEO-84 nanofibers. Results 
are presented as the relative cell viability (%) compared to the control (hHBSS, 10 mM HEPES in 
HBSS pH 7.4). Error bars are standard error of mean. N=2, n=3; N representing the number of cell 
passages and n the number of samples.  
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Evaluation of the ALA-based nanofibers as a potential drug delivery system 
 
To demonstrate the potential application of ALA-based nanofibers as a drug delivery system, 
ALA/PEO-84 nanofibers were loaded with ampicillin by including the antibiotic in the electrospun 
ALA/PEO dope, and the fibers were hereafter cross-linked with GTA. No significant changes in 
neither fiber morphology nor fiber diameter were found in the presence of ampicillin (Supporting 
Information, Figure S3A). As a proof of concept, inhibition of bacterial growth by a zone-
inhibition assay was used as a semi-quantitative measurement of ampicillin release from the 
nanofibers. Ampicillin is on the World Health Organization's List of Essential Medicines being 
used to treat infections by both Gram-positive and Gram-negative bacteria including the bacteria 
strains introduced below. In this study, we focused on inhibition of Gram-negative bacteria since 
these are intrinsically more resistant to antibiotics and thus more challenging to treat.48 
Specifically, E. coli was chosen as a model organism for Gram-negatives, P. aeruginosa is a 
clinically relevant ESKAPE pathogen and B. thailandensis was chosen as a surrogate for the 
biological warfare agent B. pseudomallei. Furthermore, the inhibition of E. coli in different phases 
of growth were investigated, as it has been found that different phases of growth can require 
different antibiotic therapies.49,50 
In order to compare the antibiotic efficacy against different bacterial species, ampicillin-loaded 
fiber mats with a fixed surface area (round discs of 10 mm in diameter) were placed on LB agar 
plates immediately after inoculating with bacteria taken from overnight cultures of E. coli, B. 
thailandensis, or P. aeruginosa. After 24 hours incubation at 37 °C, the growth of E. coli BW25113 
and E. coli ATCC11303 was inhibited with an ampicillin content as low as 1% (w/w) in the fibers 
(squares and circles, Figure 6A). The relative inhibition area correlated well with the ampicillin 
content, with saturation observed above 3% (w/w) for which the relative inhibition area was 
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approximately 1.5 and 1.9 for the E. coli strains BW25113 and ATCC11303, respectively. As 
negative control, mats of ALA/PEO-84 fibers without ampicillin had no inhibitory effect on any 
of the strains tested. In addition, ampicillin-loaded ALA/PEO-84 fibers showed no inhibition of 
an E. coli BW25113 carrying a plasmid encoding an ampicillin resistant cassette (blue triangles, 
Figure 6A) and of P. aeruginosa (green triangles Figure 6A) in line with previously reported 
findings. Only fibers loaded with 6% (w/w) ampicillin produced inhibition zones against B. 
thailandensis comparable to those measured against E. coli (diamonds, Figure 6A). Overall, these 
results clearly demonstrate the ability of the ALA-based nanofibers to encapsulate and preserve 
ampicillin.  
The capability of the ampicillin-loaded ALA-based fiber mats to inhibit E. coli BW25113 in its 
different phases of growth was evaluated. The fibers showed reduced inhibition of exponentially 
growing bacteria (purple, Figure 6B) compared to bacteria in the lag phase (red, Figure 6B). 
Specifically, ALA-based nanofiber mats loaded with 3% and 6% (w/w) ampicillin showed a 
reduction in relative inhibition area of a factor of 1.4 and 1.2, respectively, when used against 
exponentially growing bacteria compared to bacteria in the lag phase. Ampicillin-loaded ALA-
based nanofibers did not show any inhibitory activity against E. coli BW25113 in the stationary 
phase (blue, Figure 6B). This is in accordance with previously reported data.49,50 
The release of ampicillin and hence the inhibited bacterial growth in the presence of antibiotic-
loaded nanofibers were expected to be dependent on their aqueous stability. The abrupt increase 
in the relative inhibition area after 2 hours for bacteria treated in the lag phase correlates with the 
time needed for E. coli BW25113 to populate the LB agar plates (Figure 6C, Supporting 
Information, Figure S3). When applied to E. coli BW25113 in the lag phase, cross-linked (GTA 
vapor for 24 hours) and non-cross-linked fiber mats showed very similar inhibition kinetics (red 
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symbols, Figure 6C). In contrast, when applied to E. coli BW25113 in the exponential phase, non-
cross-linked fibers generated an increase in the relative inhibition area as quick as 20 min post 
application, thus twice as fast as cross-linked ALA-based fibers (purple symbols, Figure 6C). 
Moreover, the cross-linked mats had an overall higher inhibition capability 2 hours post 
application, with a relative inhibition area increase of a factor of 1.2 with respect to cross-linked 
fibers. Furthermore, non-cross-linked fibers dissolved on the LB agar within 20 min post 
application. Overall, these data demonstrates the versatility of our approach, and how the 
mechanical properties of the ALA-based fiber mats can affect the antibiotic release timescale 
depending on the specific application. 
Finally, in this setup, the possibility of using the same fiber mat to treat multiple bacterial lawns 
in series was tested. Fiber mats were firstly applied on a bacterial lawn in the lag phase and 3.5 
hours after application. When inhibition had levelled off (circles, Figure 6D), the fiber mats were 
transferred to a second bacterial lawn, also in the lag phase, on a different LB agar plate. 
Noteworthy, mats loaded with 6% (w/w) ampicillin were able to inhibit the second bacterial lawn 
with a relative inhibition zone reduced of a factor 1.3 with respect to that measured on the first 
bacterial lawn (diamonds, Figure 6D). In comparison, mats loaded with 3% (w/w) ampicillin 
showed a significantly lower effect on the second bacterial lawns (diamonds, Figure 6D). 
Importantly, after removal of the mats from the initial treated culture on LB agar, no bacterial 
regrowth were observed in the inhibition zone within 24 hours indicating not only inhibition, but 




Figure 6. A) Zone of inhibition antibacterial testing of cross-linked ALA/PEO-84 nanofiber mats 
loaded with ampicillin (amp) against various Gram-negative bacterial strains in the lag phase of 
growth and B) against E. coli BW25113 in different phases of growth. C) Zone of inhibition 
antibacterial testing of non-treated and cross-linked ALA/PEO-84 nanofibers loaded with 6% 
(w/w) ampicillin against E. coli BW25113 in the lag phase and in the exponential phase of growth, 
visualized over time. D) Zone of inhibition antibacterial testing of cross-linked ALA/PEO-84 
nanofibers loaded with 6% (w/w) ampicillin against E. coli BW25113 in the lag phase after first 
and second application of the same fiber mat on two successive bacteria lawns. Error bars are 
standard error of the mean. N≥3, where N represent the number of individual samples.  
Taken together, these data unambiguously demonstrate that ampicillin-loaded ALA-based fiber 
mats prepared by electrospinning succesfully inhibit the growth of Gram-negative bacteria in vitro 
in a concentration- and time-dependent manner. The fact that no bacterial regrowth was observed 
after removal of the nanofiber mats suggests that this treatment is capable to clear eventual 
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persisters to ampicillin at least under in vitro conditions. This capability needs to be further 
investigated with single-bacterium resolution51 by loading ALA-based fibers with antibiotics 
effective against the stationary phase of Gram-negative bacteria, which is the phase exhibiting the 
highest persister ratio.49,50  
CONCLUSIONS 
 
Based on the favorable properties of neat ALA as a natural carrier and the benefits of a well-
controlled processing method such as electrospinning, our findings offer a robust and highly 
tunable platform for developing novel DDSs. We provide a sustainable and environmentally 
friendly platform for production of highly tunable and biocompatible nanofibers obtained by 
electrospinning of an aqueous solution containing the isolated milk protein ALA. We demonstrate 
the possibility to produce nanofibers with a content of ALA up to 84% (w/w), while using only a 
small amount of PEO as a carrier polymer and importantly avoiding the use of any toxic solvents. 
The nanofibers possess high tunability in terms of fiber diameter and mechanical properties by 
varying the ALA concentration. Cross-linking (either physically or chemically) of the nanofibers 
gives the possibility to produce protein nanofibers ranging from fast-dissolving and highly flexible 
networks to more insoluble solid forms. The produced nanofiber-based materials showed good cell 
culture compatibility, and are capable of encapsulating functional ampicillin. Indeed, when tested 
against Gram-negative bacteria, ampicillin-loaded nanofibers showed an extraordinary efficiency 
in inhibiting Gram negative bacterial growth in vitro. The degree of bacterial inhibition depended 
on both the specific growth phase of the bacteria culture and the degree of cross-linking of the 
ampicillin-loaded nanofibers, demonstrating how the tunability of the system affects the drug 
delivery properties. Importantly, after removal of the nanofibers, we do not observe bacterial re-
growth, suggesting that this treatment is capable to clear eventual persisters to ampicillin under in 
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vitro conditions. This can pave the way for addressing one of the most critical challenges in 
medical sciences related to the dramatic increase of bacteria resistance towards standard antibiotics 
treatment. Finally, ALA has a number of extraordinary properties as a nutrient; for example 
Lacprodan®ALPHA-10, a whey protein fraction with minimum 41% ALA, was recently (2019) 
FDA-approved as an ingredient ‘generally recognized as safe’ (GRAS) in infant formula to support 
the growth of infants.52 The protein was also shown to have a key role in the treatment of a number 
of human diseases, including some specific cancers in the complex HAMLET/BAMLET. In this 
respect, our study shows that once disintegrated in water, nanofibers release ALA molecules 
structurally resembling ALA in its native state. Via our approach, while keeping the original native 
structure, a novel nanofiber-based solid form of ALA can be adapted to the specific desired 
application. This makes our platform of even more general interest, and the relevance of our results 
spans from green chemistry and material sciences to drug delivery and biopharmaceutics. 
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